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ABSTRACT
Effects of Transcutaneous Electrical Nerve Stimulation on Voluntary
Quadriceps Activation and Vertical Ground Reaction Force
During Walking in Subjects with Experimental Knee Pain
Seong Jun Son
Department of Exercise Sciences, BYU
Master of Science
Context: Knee pain is a common symptom in knee pathology and is associated with
alterations in quadriceps activation and movement patterns. Reducing pain through intervention
may help reestablish neuromuscular function. The independent effects of knee pain are difficult
to examine and unclear. Objective: To investigate the effects of transcutaneous electrical nerve
stimulation (TENS) on quadriceps activation and vertical ground reaction force (VGRF) during
walking. Design: Crossover. Setting: Laboratory. Subjects: 15 in the TENS group (10M and 5F,
23.5 ± 2.8 yrs, 70.5 ± 12.5 kg, 178.1 ± 7.4 cm), and 15 in the sham group (10M and 5F, 22.5 ±
2.0 yrs, 72.1 ± 13.7 kg, 177.5 ± 9.3 cm). Interventions: Subjects underwent three experimental
conditions (pain, sham, and control). Measurements were recorded across four time points
(preinfusion, infusion, treatment, and posttreatment). Hypertonic or isotonic saline, respectively,
was infused into the infrapatellar fat pad for 48 minutes (total 7.7 mL). The TENS group
received a 20-minute treatment. A sham treatment was administered to the sham group. Main
Outcome Measures: Perceived knee pain on a 10-cm visual analog scale, knee extension
maximum voluntary isometric contraction (MVIC) normalized to body mass, knee extension
central activation ratio (CAR), and VGRF. Results: Knee pain peaked at 4 cm during infusion
and remained consistent across time in the sham group (F2,28 = 49.90, P < 0.0001), while knee
pain gradually decreased to 1.5 cm following TENS treatment (F2,28 = 23.11, P < 0.0001). A
group x condition x time interaction was detected for both the MVIC (F6,168 = 2.92, P < 0.01)
and CAR (F6,168 = 3.03, P < 0.008) measurements. Post hoc analysis revealed that the infusion
of hypertonic saline reduced knee extension MVIC by 29% in the TENS group, and by 26% in
the sham group (P < 0.05). However, while the MVIC remained depressed by 26% following
sham treatment, the MVIC was found to improve by 12% following TENS treatment (P < 0.05).
Similarly, a 10% decrease in CAR was detected in both sham and TENS groups prior to
treatment. This 10% deficit held, with a 9% deficit following sham treatment, while the deficit of
CAR was improved by 4% following TENS treatment (P < 0.05). For the TENS group, infusion
of hypertonic saline changed VGRF at initial loading, midstance, and push-off phase. VGRF was
only different at initial loading and push-off phase following TENS treatment. For the sham
group however, sham treatment did not restore VGRF, showing alterations in initial loading,
midstance, and push-off phase (α = 0.05). Conclusions: Infusion of hypertonic saline increased
perceived knee pain, reduced knee extension MVIC, reduced CAR, and altered VGRF over some
of stance phase. TENS lessened the deficits in MVIC, CAR, and VGRF, suggesting decreased
muscle inhibition and improved movement function.
Keywords: transcutaneous electrical nerve stimulation, maximum voluntary isometric
contraction, central activation ratio, vertical ground reaction force, hypertonic saline
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Introduction
Knee pain is a common symptom in knee pathology exhibited frequently in athletes and
nonathletes.1,2 Among all knee complaints, knee pain accounts for 40% of symptoms reported in
sports medicine clinics.3,4 Knee osteoarthritis (OA), which is a possible result of long-term knee
pain,5 affected nearly 27 million adults (12.1%) in the U.S. in 2008.6 Acutely, knee pain
decreases quadriceps motor function7,8 and alters movement biomechanics.9 It also changes
movement biomechanics over the long-term, including climbing stairs and walking.1,10,11
Although etiologies and diagnoses vary, it is obvious that knee pain causes short- and long-term
changes in lower extremity neuromuscular function.1,5,7-9,12
The acute effects of knee pain include alterations in quadriceps activation.7,8 Among
other lower extremity muscle groups, the quadriceps contribute to the stability of the knee joint.
The quadriceps could play an important role in absorbing impact shock and distributing load
across the knee joint.13-15 The quadriceps work eccentrically during initial stance to help proper
knee joint loading, and to decelerate the limbs in terminal swing before heel strike, thereby
decreasing knee load during initial stance.16 However, quadriceps function is reduced due to
knee pain.81,7,17 Quadriceps inhibition is an immediate effect of knee pain, and eventually gives
rise to chronic quadriceps muscle weakness and atrophy,18 which in turn is likely associated with
altered knee joint loading.15 Since decreased quadriceps function due to experimental knee pain
(EKP) is likely to cause a reduction of internal knee extension moments during walking,9
reduced quadriceps activity can lead to alterations in vertical ground reaction force (VGRF). It is
for these reasons that we and others1,5,17 speculate that the quadriceps may play a critical role in
prevention of degenerative knee joint disease.
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Chronic knee pain likely contributes to knee OA genesis and progression and other longterm pathologies because it results in abnormal knee joint load during gait.5,19 Pain-avoidance
gait patterns are the first stage of the pathogenesis of medial knee OA.20-22 Since VGRF is a
primary contributor to knee load, knee joint muscle function,23 and joint loading rate,24 the
observation of VGRF during painful walking can help us better understand the effects of knee
pain on knee joint muscle function and corresponding knee joint load.
To alleviate acute and chronic effects of knee pain, a disinhibitory intervention is likely
necessary. Among all disinhibitory interventions, including cryotherapy, thermotherapy,
electrotherapy, and manual therapy, transcutaneous electrical nerve stimulation (TENS) could
offer the most potential for reducing knee pain25,26 and increasing quadriceps activation.27,28 It is
thought that TENS stimulates large-diameter sensory nerves, increasing inhibition of T cells and
decreasing the ability of pain signals to reach the brain.29 Sensory signals created by TENS are
considered to be an excitatory stimulus which supersedes inhibitory sensory signals, and
improves motor output.27 As a result, early TENS could prevent the consequences of knee pain,
including perceived knee pain, quadriceps muscle inhibition, altered VGRF, and altered knee
joint loading.
Recent studies found that subjects with experimental knee pain (EKP) showed a 34%
reduction of knee extension maximal voluntary isometric contraction (MVIC),8 a 5% reduction
of central activation ratio (CAR),8 and a decrease in peak VGRF during gait.9 However, no study
has looked at the effects of TENS on quadriceps activation and VGRF during gait in subjects
with EKP.

2

The purpose of this study was to investigate the effects of TENS on quadriceps activation
and VGRF during gait in subjects with EKP. We hypothesized that EKP could reduce quadriceps
activation and VGRF, and TENS could improve deficits of the quadriceps activation and VGRF.
Methods
Experimental Design
This study was conducted as a crossover, controlled laboratory trial. Independent
variables were: four time intervals (preinfusion, infusion, treatment, and posttreatment), three
conditions (pain, sham, and control), and two treatment groups (TENS and sham). Dependent
variables were: perceived knee pain, knee extension MVIC, knee extension CAR, and VGRF
during walking.
Subjects
Thirty volunteer subjects were recruited from a college population: 15 subjects in the
TENS group (23.5 ± 2.8 yrs, 70.5 ± 12.5 kg, 178.1 ± 7.4 cm), and 15 subjects in the sham group
(22.5 ± 2.0 yrs, 72.1 ± 13.7 kg, 177.5 ± 9.3 cm). To participate, each subject had to be physically
active (exercising at least three times a week for 30 min), with no history of neurological
disorders, no history of lower extremity orthopedic surgery, and no lower extremity injury in the
past six months. Moreover, no pain medication was allowed 12 hours before data collection.
Each subject was randomly assigned to either the TENS or sham treatment group. Each subject
was required to come three times and each visit was separated by at least a 48-hour washout
interval between each data collection. We asked each subject to maintain his or her physical
activity prior to and between the data collection sessions. Prior to participation, an informed
consent form was signed by each subject.
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Instruments
Knee extension MVIC was measured using a Biodex dynamometer (system Pro 4,
Biodex, Shirley, NY) with a sampling rate of 100 Hz. After shaving and cleaning electrode
locations, 2 electrodes (Dura-Stick II, Chattanooga, Hixson, TN; 70x127mm) were placed on the
proximal-lateral aspect of the thigh and the distal-medial aspect of the thigh. When knee
extension MVIC reached a plateau, a supramaximal electrical stimulus (100 pps, 600 µsec, 10
trains in 100 ms duration, and 125 V with peak output current 450mA) was manually transmitted
to the quadriceps via two electrodes. To measure CAR, the S88 grass stimulator with the SIU8T
transformer stimulus isolation unit (Grass-Telefactor, West Warwick, RI) was used to produce a
supramaximal electrical stimulus.
VGRF was recorded using a force-sensing tandem treadmill (AMTI, Watertown, MA)
with a sampling rate of 1200 Hz. VGRF data was smoothed by a fourth-order Butterworth filter
with cutoff frequency of 25 Hz.30 The unfiltered signal showed noise and 25 Hz cutoff frequency
eliminated the noise effectively from the original data.
Perceived knee pain was measured using a 10-cm visual analog scale (VAS).31 Every 2
minutes, each subject was asked to rate their perceived knee pain level.
Procedures
Each subject performed a 5-minute walking warm-up on the treadmill. After warm-up,
electrode placement points on the anterior thigh were shaved and cleaned with alcohol wipes.
Two electrodes were placed on the anterior thigh, one at the proximal-lateral aspect of the thigh
and the other at the distal-medial aspect of the thigh (Figure 1).
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Measure Knee Extension MVIC and CAR
Each subject was positioned on the Biodex with the knee and hip secured at 90° and 85°
flexion using a goniometer (Figure 2). The subject was requested to execute knee extension
MVIC. When the MVIC reached a plateau approximately 1.5 to 2 s after each bout of MVIC, a
supramaximal electrical stimulus was manually transmitted to two electrodes on the anterior
thigh. The CAR was calculated by dividing knee extension MVIC by the force generated by the
superimposed burst (SIB) plus knee extension MVIC: CAR = (knee extension MVIC) / (SIB +
knee extension MVIC).8,32
Measure VGRF
VGRF was recorded (1200 Hz) during 30 s of walking at a self-selected speed. To
minimize influence of speed on VGRF, the preinfusion walking speed was used as a covariate in
the statistical analyses.
Pain Infusion
After preinfusion measurements, EKP was induced in each subject’s dominant leg. A 20gauge flexible catheter (Becton Dickinson Medical System, Sandy, UT) was inserted into the
lateral infrapatellar fat pad. The angle of the catheter insertion was 45° in an inferior-medial
direction to the middle of the infrapatellar fat pad with a depth of 1 cm (Figure 3). Using a 100cm extension tube (B. Braun, Bethlehem, PA), the catheter was connected to a 30 mL syringe,
which was attached to a portable infusion pump (Graseby Medical, Hertfordshire, UK). This
portable pump created a continuous saline flow of 0.16 mL·min for 48 minutes (total 7.7 mL).
For the pain condition, 5% hypertonic saline (B. Braun, Irvine, CA) was infused. After
the initiation of infusion, each subject assumed three different positions (supine for 3 min, sit
upright for 3 min, and stand for 2 min), to help with familiarization to the effects of the infusion
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(Figure 4, 5, and 6). For the sham condition, 0.9% isotonic saline (Hospira, Inc., Lake Forest, IL)
was infused. For the control condition, measurements were recorded at each of the time intervals.
The control condition was identical to the other sessions, except that no infusion was
administered.
TENS Treatment
TENS treatment was given to each subject in the TENS group 14 min after initial
infusion. The skin around the knee joint was shaved and cleaned with alcohol wipes to ensure the
adherence of electrodes. Four self-adhesive square electrodes were placed on the superior-medial
and superior-lateral, and the inferior-medial and inferior-lateral borders of the patella (Figure
7).27 Two TENS currents covered the entire knee joint. The TENS protocol was set at a
continuous asymmetric biphasic square-pulse wave with a pulse width of 120 and a pulse rate of
180.33 The intensity of TENS was increased until a visible contraction of the vastus medialis was
seen. Then, the intensity of stimulus was reduced until no contraction was seen or felt by
investigators.27 The duration of treatment was set for 20 min.
Sham Treatment
Sham treatment was given to the sham group. Each subject was told that an electrical
stimulation was set to subsensory level and the indicator light was on during treatment (Figure
8). This approach allowed us to keep the sham group blinded to receiving placebo treatment. The
preparation for electrodes was the same with the TENS group as previously described.
Data Reduction
We recorded the MVIC and CAR at four time intervals (preinfusion, infusion, treatment,
and posttreatment). Each measurement consisted of three trials. Between each of the MVIC and
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CAR, there was a 30-second resting period. Means of the MVIC and CAR were calculated from
three trials.
We measured walking VGRF for 30 s at the four time intervals. The smoothed VGRF
corresponding to the first five stance phases of each 30-s collection were imported into
MATLAB and normalized to weight (amplitude) and stance (time). Then we averaged the VGRF
trace across the five observed stance phases.
Statistical Analysis
Means of the MVIC and CAR were calculated from three trials at each of the four time
intervals. To detect difference in infusion, treatment, and posttreatment measurements compared
to preinfusion (baseline) measurements, 2 x 3 x 4 mixed model ANOVAs with repeated
measures were used for: perceived knee pain, knee extension MVIC, and knee extension CAR. A
functional analysis of variance (FANOVA) was used to determine differences between groups
and times for VGRF (α = 0.05) over the entire stance phase. A FANOVA allows for a
comparison of treatment effects as functional effects (polynomial functions) over the entire
stance phase, rather than univariate or multivariate (discrete values) effects. In other words, we
can detect whether there is a difference between the factors, and where in the stance phase those
differences exist. As the means for inference, any difference between factors (effect) that is not
equal to zero (no effect) at 95% confidence level is deemed statistically and clinically significant.
Results
Perceived Knee Pain
Perceived knee pain peaked at 4 cm (F2,28 = 49.90, P < 0.0001) on a 10-cm VAS during
infusion in both the sham and TENS groups. While perceived knee pain remained consistent
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across time intervals following sham treatment, perceived knee pain was gradually decreased to
1.5 cm (F2,28 = 23.11, P < 0.0001) following TENS treatment (Figure 9).
Knee Extension MVIC
A group x condition x time interaction was detected for MVIC (F6,168 = 2.92, P < 0.01)
and CAR (F6,168 = 3.03, P < 0.008) measurements. Post hoc analysis revealed that EKP acutely
reduced knee extension MVIC by 29% (preinfusion = 3.20±0.66 Nm/kg, infusion = 2.28 ± 0.98
Nm/kg) in the TENS group, and by 26% (preinfusion = 3.34 ± 0.80 Nm/kg, infusion = 2.47 ±
0.77 Nm/kg) in the sham group (P < 0.05). However, while the MVIC remained depressed by
26% following sham treatment (treatment = 2.48 ± 0.69 Nm/kg, posttreatment = 2.49 ± 0.61
Nm/kg), reduced MVIC was improved by 12% following TENS treatment, which was
statistically no different from preinfusion values (Figure 10).
Knee Extension CAR
Similarly, a 10% decrease in CAR was detected in both sham (preinfusion = 99 ± 1%,
infusion = 89 ± 7%) and TENS groups (preinfusion = 98 ± 1%, infusion = 88 ± 12%) prior to
treatment. While a 9% deficit remained following sham treatment (treatment = 89 ± 6%,
posttreatment = 90 ± 6%), decreased MVIC was improved from 9% to 4% following TENS
treatment, which was statistically no different from preinfusion values (P < 0.05) (Figure 11).
VGRF
Means of VGRF over five stance phases during 30 seconds of walking were calculated in
both TENS and sham groups with three conditions in four time intervals. The stance phase of
walking is divided into 4 phases, including 0%–17% (loading response), 17%–50% (midstance),
50%–83% (terminal stance), and 83%–100% (preswing).34 Figures 12–17 show differences of
VGRF between factors. The shaded areas represent 95% confidence intervals for the population
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mean effect size. When the shaded area crosses the dotted line, clinically and statistically
significant differences exist. The functional analysis showed that VGRF was altered during
infusion measurements compared to preinfusion measurements in the TENS group (Figure 12).
After TENS treatment, the difference of VGRF areas was reduced (Figure 13). During 6-min
posttreatment measurements, the difference of VGRF areas was even more reduced (Figure 14).
For the sham group, the functional analysis revealed that VGRF was also changed following
infusion compared to preinfusion measurements (Figure 15). After sham treatment, there still
existed some differences of VGRF (Figure 16). During posttreatment measurements, altered
VGRF was consistently revealed (Figure 17). No difference was shown in sham and control
conditions in both TENS and sham groups.
Discussion
The primary purpose of this study was to examine the acute effects of TENS on voluntary
quadriceps activation and walking biomechanics in subjects with EKP. We hypothesized that
TENS treatment would decrease perceived pain intensity and mitigate associated alterations for
MVIC, CAR, and VGRF. The present data generally support our hypotheses. The present EKP
model acutely produced knee pain for 48 min while being infused, and caused a reduction of
quadriceps activation and alterations in walking VGRF. After TENS treatment, quadriceps
inhibition was somewhat disinhibited, as shown by the mitigation of the altered MVIC and CAR
due to EKP. The TENS treatment also caused walking VGRF to move in a return direction
toward normal relative to the altered VGRF, due to EKP throughout stance. Due to confounding
variables such as inflammation, effusion, joint degeneration, and/or receptor damage, it is
difficult to investigate the independent effects of knee pain on alterations in lower extremity
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neuromechanics. However, our EKP model allowed us to examine the effects of EKP as an
independent variable by eliminating the aforementioned confounding variables.
Perceived Knee Pain
Many studies1,3,7-9,35 have investigated the effects of EKP on lower extremity
neuromuscular alterations. Bennell et al.35 suggested that the quality, regions, and patterns of
pain caused by EKP are similar to those in patients with clinical knee pain. Hypertonic saline,
placed in the infrapatellar fat pad, is a safe and efficient method to produce anterior knee pain
through release of substance P, a substance that is released through the c-fiber pathways in the
dorsal horn, which is commonly seen in musculoskeletal pain.36 Several anatomic structures and
regions may produce anterior knee pain such as the infrapatellar fat pad, patellar tendon, joint
capsule, medial and lateral retinaculum, and anterior synovium.35 Among those aforementioned
regions, the infrapatellar fat pad has a good blood supply from the synovial membrane35 and is
innervated by a posterior articular nerve.37 Investigators reported perceived knee pain via
arthroscopic palpation of the interior knee without intra-articular anesthesia.38 They noted that
the fat pad is highly sensitive to pain.38
We infused 7.7 mL (0.16 mL·min for 48 min) of hypertonic saline into the infrapatellar
fat pad to induce the EKP condition. An average of perceived knee pain level at 4 cm in the
present study was consistent with previous research, which reported 4.29 cm by infusing 6.6 mL
(0.3 mL·min for 22 min).9 The present study examined the effects of EKP for 48 min. While the
previous single-injection model provides a very short window of time of significant pain
(approximately 5 min), the current model allowed us a longer duration to examine the effects of
EKP on lower extremity neuromuscular alterations.
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Knee Extension MVIC
Multiple researchers have attributed muscle inhibition to pain.23,39-41 After knee injuries,
quadriceps inhibition is commonly observed in previous studies.42-46 The muscle inhibition has
been investigated in clinical anterior knee pain,42,44,45,47,48 experimentally induced knee pain,1,7,8
and postoperative knee pain.25,49,50 One study reported that patients with unilateral anterior knee
pain showed bilateral quadriceps inhibition,44 which suggests that knee pain contributes to
negative sensorimotor function in the contralateral limb. Since the present study only calculated
knee extension MVIC in the involved limb, we can only speculate that EKP could decrease force
output in the uninvolved limb.
Our results show that EKP acutely reduced knee extension MVIC by 29% in the TENS
group and by 26% in the sham group compared to preinfusion measurements. The results are
consistent with previous research that showed that EKP (a 1 mL single injection of hypertonic
saline) decreased knee extension MVIC.7,8 When EKP is administered, afferent activity from
nociceptor may give rise to alterations in the excitability of spinal reflex pathways, which
contributes to a reduction of quadriceps alpha motoneuron excitability.51
Previous authors supported the idea that TENS treatment plays a critical role in a
decrease in perceived pain in musculoskeletal injuries.24,26 Nociceptors in the patella fat pad are
stimulated by hypertonic saline through the group III and IV afferent fibers.52 Afferent sensory
stimuli (knee pain signals) are transmitted to the brain through both large- and small-diameter
nerve fibers.29 Both sensory stimuli meet at the T cell, where the gate is located.29 The substantia
gelatinosa, which transmits inhibitory signals to the T cell, obtains different stimuli from both
large- and small-diameter fibers. TENS treatment aims to stimulate large-diameter sensory
nerves, resulting in an increase in inhibitory effects on the T cell which closes the gate, where
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sensory pain signals are unable to transmit to the brain.29 In the present study, perceived knee
pain was reduced from 4 cm (peak) to 1.2 cm following TENS treatment. Our findings are
consistent with previous studies.25,26 However, we do not know how a reduction of pain intensity
affects an increase in quadriceps activation.
Many research studies have reported the disinhibitory effects of TENS on quadriceps
activation in knee pathologies.27,28,32 A 20-min TENS treatment effectively reduced the amount
of quadriceps inhibition arising from EKP, and it seems to be more effective 6-min posttreatment
in the present study. The disinhibitory mechanism of TENS on quadriceps function is not fully
understood. However, we can speculate that TENS may stimulate inhibitory reflex mechanisms,
which lead to the excitation of inhibited motor neurons.27 Sensory stimulation created by TENS
is considered as the excitatory stimulus, which supersedes inhibitory sensory signals, thereby
improving motor output.27 We speculate that TENS may diminish quadriceps muscle inhibition
by: inhibiting the activity of the Ib inhibitory interneuron, creating excitation of the Ia excitatory
interneuron leading to an excitatory potential at the motoneuron pool, and/or activating
supraspinal centers to abate the effects of muscle inhibition via descending inhibitory fibers,
which connect to the Ib interneuron (an integrative station for sensory signals).27
Knee Extension CAR
Even though central activation failure possibly can result from decreased voluntary force
production,8 altered central neural reflex pathways,53 or reduced maximum firing rate,54 the main
cause of a reduction of CAR is poorly understood. A CAR of 1.0 represents a complete muscle
contraction, and a CAR ≥ 0.95 is considered full muscle activation.55 Previous research showed
that the relationship between CAR and MVIC is commonly curvilinear, showing a CAR of 0.8 is
equivalent to a MVIC of 60% (R² = 0.98; 98% of accurate prediction).55 In the present study, a
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CAR of 0.9 is proportionate to a MVIC of 75% under pain condition. As knee extension MVIC
improved from 71% to 88% following TENS treatment, CAR increased from 0.9 to 0.96. We
speculate that TENS possibly contributes to increasing excitation of the motor neurons and firing
rate, suggesting increased force production and decreased muscle inhibition. Due to the nature of
curvilinear shape (the flat portion of the curve at the end), CAR is not a sensitive measure at
greater than 90% of MVIC.55 Healthcare professionals should consider the curvilinear nature of
the relationship as they interpret CAR values relative to MVIC values.55
VGRF
Presently, EKP altered VGRF. Infusion of hypertonic saline in the TENS group resulted
in a reduction of VGRF at initial loading response (0%–4%), early midstance (16%–32%), and
terminal stance (69%–91%), and an increase of VGRF at midstance (44%–67%) (Figure 12).
Similarly, a reduction of VGRF is also observed in the sham group at slightly different stance
phases (Figure 15). This fits with previous findings that showed decreased peak VGRF due to
knee pain in patients with knee OA.12,56 In addition, our findings are consistent with previous
data published by Seeley et al., showing a reduction of peak VGRF in subjects with EKP.9
Decreased VGRF during the loading response and push-off phases of walking are likely
associated with quadriceps inhibition resulting from EKP as knee extensors contribute to vertical
acceleration of the center of mass during loading response and push-off phase.9,16 Normal
quadriceps function likely plays a critical role in knee joint loading during walking.5,7-9
The present study has three important key points: how EKP affects quadriceps function,
how altered muscle function affects articular cartilage health, and how TENS appears to mitigate
the effects of EKP on quadriceps activation.
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EKP significantly results in a decrease in knee extensors function and changes in knee
joint load through an unloading strategy, which may cause altered VGRF in certain parts of the
stance phase. Quadriceps strength contributes to proper knee joint load during initial loading
response and push-off phase of gait.9,23 However, since EKP gives rise to a reduction of
quadriceps strength, knee joint load is consequently changed in the present study. Altered VGRF
in the present study can be explained by two possible perspectives: poor quadriceps activation
and an unloading strategy. A reduction of quadriceps activation may likely be associated with a
subconscious alteration in voluntary effort, resulting in fear of damaging or increasing knee pain
from the involved limb.57,58 Inhibited quadriceps function due to knee pain consequently
contributes to a reduction of internal knee extension moments in the involved limb, which
ultimately results in altered knee joint load.9 In addition, altered VGRF is possibly related to an
unloading strategy due to perceived knee pain. The unloading strategy might also be related to
perception of pain, which makes subjects feel fear for damaging or provoking pain more during
movement from the involved limb.57,58
Previous studies reported that participants with clinical knee pain showed a greater knee
joint load response in the uninvolved limb rather than the involved limb.59 This unloading motor
strategy can result from perceived pain and/or quadriceps dysfunction. The abnormal shape of
the VGRF is often observed, showing an absence of two distinguishable peaks at initial loading
response and push-off, and an increase in VGRF at midstance. Since we did not calculate VGRF
in the uninvolved limb, we can only speculate that both an intentional unloading motor strategy
and poor quadriceps coordination may contribute to alterations in VGRF. Importantly, we
observed an increase in VGRF at only midstance while a decrease in VGRF was shown in initial
loading response and terminal stance phase. We speculate that altered neuromuscular strategies
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in both unloading and poor muscle control might change the characteristic of knee joint load
responses in both limbs. For example, during gait cycle transitions from heel-strike to midstance,
subjects may be able to rely on knee joint load in the uninvolved limb at initial heel-strike since
heel-strike is supported by double-leg. However, once double-leg support is passed, subjects are
only able to rely on their knee joint load in the involved limb. Therefore, unsmooth gait
transitions from heel-strike to midstance may likely contribute to an increase in VGRF at
midstance.
Articular cartilage health is highly associated with surrounding knee joint muscle
function and load.5,7,60 Quadriceps activation failure is a critical issue in knee joint loading since
it may influence all aspects of lower extremity movement biomechanics. This impairment begins
with altered motor recruitment patterns, which lead to abnormal joint loading, and eventually
may accelerate the long-term effects of joint disease progression. Altered gait patterns or motor
strategy are likely associated with articular cartilage health in the knee joint.9,19 Many studies
showed that altered gait patterns due to knee pain are severely harmful for articular cartilage in
the knee joint because it may accelerate the rate of progression of articular cartilage.5,9,19,23,59
Previous research using a knee OA population reported that knee pain resulted in a greater
loading response in the uninvolved limb rather than the involved limb.59 This altered loading
strategy may result in chronic asymmetric joint load and muscle function.9,60 If this is consistent
over the long-term, the progression of degenerative joint disease may not be avoidable.
Therefore, restoring altered gait patterns and reducing quadriceps dysfunction could be a primary
goal for healthcare professionals because those factors are highly related to cartilage health
condition.

15

TENS mitigated the effects of EKP on quadriceps activation and walking VGRF in the
present study. TENS treatment not only decreased perceived pain, but also improved motor
strategy. We speculate that the effects of TENS on both perceived pain and quadriceps function
are likely related to an increase in internal knee extension moments which contribute to walking
VGRF. However, we are not sure which factor (decreased pain or increased quadriceps
activation) influence VGRF more. Presently, VGRF improvement appeared to be related to
quadriceps function and played a pivotal role in gait patterns by absorbing impact shock and
distributing load across the knee joint.16
Conclusion
There were three main findings in this study. First, our EKP model produced consistent
knee pain for 48 min while being infused. Second, EKP altered lower extremity muscle function
(knee extension MVIC and CAR) and neuromechanics during walking (VGRF). Last, TENS
treatment mitigated the aforementioned alterations. This was the first study to investigate effects
of TENS on lower extremity neuromechanics.

16

References
1.

Hodges PW, Mellor R, Crossley K, Bennell K. Pain induced by injection of hypertonic
saline into the infrapatellar fat pad and effect on coordination of the quadriceps muscles.
Arthritis & Rheumatism: Arthritis Care & Research. 2009;61(1):70-77.

2.

Cesarelli M, Bifulco P, Bracale M. Quadriceps muscles activation in anterior knee pain
during isokinetic exercise. Medical Engineering & Physics. 1999;21(6-7):469-478.

3.

DeHaven KE, Lintner DM. Athletic injuries: comparison by age, sport, and gender.
American Journal of Sports Medicine. 1986;14(3):218-224.

4.

Kannus P, Natri A, Paakkala T, Järvinen M. An outcome study of chronic patellofemoral
pain syndrome. Seven-year follow-up of patients in a randomized, controlled trial.
Journal of Bone and Joint Surgery. 1999;81(3):355-363.

5.

Henriksen M, Graven-Nielsen T, Aaboe J, Andriacchi TP, Bliddal H. Gait changes in
patients with knee osteoarthritis are replicated by experimental knee pain. Arthritis Care
& Research. 2010;62(4):501-509.

6.

Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the Prevalence of Arthritis
and Other Rheumatic Conditions in the United States Part II. Arthritis & Rheumatism.
2008;58(1):26-35.

7.

Henriksen M, Rosager S, Aaboe J, Graven-Nielsen T, Bliddal H. Experimental Knee Pain
Reduces Muscle Strength. Journal of Pain. 2011;12(4):460-467.

8.

Park J, Hopkins JT. Induced anterior knee pain immediately reduces involuntary and
voluntary quadriceps activation. Clinical Journal of Sport Medicine. 2013;23(1):19-24.

17

9.

Seeley MK, Park J, King D, Hopkins JT. A Novel Experimental Knee-Pain Model
Affects Perceived Pain and Movement Biomechanics. Journal of Athletic Training.
2013;48(3):337-345.

10.

Cowan SM, Bennell KL, Hodges PW, Crossley KM, McConnell J. Delayed onset of
electromyographic activity of vastus medialis obliquus relative to vastus lateralis in
subjects with patellofemoral pain syndrome. Archives of Physical Medicine and
Rehabilitation. 2001;82(2):183-189.

11.

Hinman RS, Bennell KL, Metcalf BR, Crossley KM. Delayed onset of quadriceps
activity and altered knee joint kinematics during stair stepping in individuals with knee
osteoarthritis. Archives of Physicla Medicine and Rehabilitation. 2002;83(8):1080-1086.

12.

Zeni JA, Higginson JS. Differences in gait parameters between healthy subjects and
persons with moderate and severe knee osteoarthritis: A result of altered walking speed?
Clinical Biomechanics. 2009;24(4):372-378.

13.

Hurley MV. The role of muscle weakness in the pathogenesis of osteoarthritis. Rheumatic
Diseases Clinics of North America. 1999;25(2):283.

14.

Lindstrom M, Fellander-Tsai L, Wredmark T, Henriksson M. Adaptations of gait and
muscle activation in chronic ACL deficiency. Knee Surgery, Sports Traumatology,
Arthroscopy. 2010;18(1):106-114.

15.

Lewek M, Rudolph K, Axe M, Snyder-Mackler L. The effect of insufficient quadriceps
strength on gait after anterior cruciate ligament reconstruction. Clinical Biomechanics.
2002;17(1):56-63.

18

16.

Jefferson RJ, Collins JJ, Whittle MW, Radin EL, O'Connor JJ. The role of the quadriceps
in controlling impulsive forces around heel strike. Proceedings of The Institution of
Mechanical Engineers. Part H, Journal of Engineering in Medicine. 1990;204(1):21-28.

17.

Cheing GLY, Hui-Chan CWY. The motor dysfunction of patients with knee osteoarthritis
in a Chinese population. Arthritis & Rheumatism: Arthritis Care & Research.
2001;45(1):62-68.

18.

Hurley MV, Jones DW, Newham DJ. Arthrogenic quadriceps inhibition and
rehabilitation of patients with extensive traumatic knee injuries. Clinical Science.
1994;86(3):305-310.

19.

Creaby MW, Bennell KL, Hunt MA. Gait Differs Between Unilateral and Bilateral Knee
Osteoarthritis. Archives Physical Medicine and Rehabilitation. 2012;93(5):822-827.

20.

Andriacchi TP, Mündermann A. The role of ambulatory mechanics in the initiation and
progression of knee osteoarthritis. Current Opinion in Rheumatology. 2006;18(5):514518.

21.

Andriacchi TP, Mündermann A, Smith RL, Alexander EJ, Dyrby CO, Koo S. A
framework for the in vivo pathomechanics of osteoarthritis at the knee. Annals of
Biomedical Engineering. 2004;32(3):447-457.

22.

Miyazaki T, Wada M, Kawahara H, Sato M, Baba H, Shimada S. Dynamic load at
baseline can predict radiographic disease progression in medial compartment knee
osteoarthritis. Annals of Rheumatic Diseases. 2002;61(7):617-622.

23.

Childs JD, Sparto PJ, Fitzgerald GK, Bizzini M, Irrgang JJ. Alterations in lower
extremity movement and muscle activation patterns in individuals with knee
osteoarthritis. Clinical Biomechanics. 2004;19(1):44-49.

19

24.

Shelburne KB, Torry MR, Pandy MG. Contributions of muscles, ligaments, and the
ground-reaction force to tibiofemoral joint loading during normal gait. Journal of
Orthopaedic Research. 2006;24(10):1983-1990.

25.

Arvidsson I, Eriksson E. Postoperative TENS pain relief after knee surgery: objective
evaluation. Orthopedics. 1986;9(10):1346-1351.

26.

Robinson AJ. Transcutaneous electrical nerve stimulation for the control of pain in
musculoskeletal disorders. Journal of Orthopaedic and Sports Physical Therapy.
1996;24(4):208-226.

27.

Hopkins JT, Ingersoll CD, Edwards J, Klootwyk TE. Cryotherapy and transcutaneous
electric neuromuscular stimulation decrease arthrogenic muscle inhibition of the vastus
medialis after knee joint effusion. Journal of Athletic Training. 2002;37(1):25-31.

28.

Pietrosimone BG, Hart JM, Saliba SA, Hertel J, Ingersoll CD. Immediate Effects of
Transcutaneous Electrical Nerve Stimulation and Focal Knee Joint Cooling on
Quadriceps Activation. Medicine & Science in Sports Exercise. 2009;41(6):1175-1181.

29.

Knight KL. Therapeutic modalities. 3rd ed. Champaign, IL. 2001:98-212.

30.

Kram R, Griffin TM, Donelan JM, Chang YH. Force treadmill for measuring vertical and
horizontal ground reaction forces. Journal of Applied Physiology. 1998;85(2):764-769.

31.

Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement
of acute pain. Academic Emergency Medicine. 2001;8(12):1153-1157.

32.

Pietrosimone BG, Saliba SA, Hart JM, Hertel J, Kerrigan DC, Ingersoll CD. Effects of
Transcutaneous Electrical Nerve Stimulation and Therapeutic Exercise on Quadriceps
Activation in People With Tibiofemoral Osteoarthritis. Journal of Orthopaedic and
Sports Physical Therapy. 2011;41(1):4-12.

20

33.

Prentice W. Therapeutic Modalities in Sports Medicine. 3rd ed. St Louis, MO: Mosby;
1994:409-415.

34.

Ounpuu S. The biomechanics of walking and running. Clinics in Sports Medicine.
1994;13(4):843-863.

35.

Bennell K, Hodges P, Mellor R, Bexander C, Souvlis T. The nature of anterior knee pain
following injection of hypertonic saline into the infrapatellar fat pad. Journal of
Orthopaedic Research. 2004;22(1):116-121.

36.

Arendt-Nielsen L, Graven-Nielsen T, Svarrer H, Svensson P. The influence of low back
pain on muscle activity and coordination during gait: a clinical and experimental study.
Journal of Pain. 1996;64(2):231-240.

37.

Kennedy JC, Alexander IJ, Hayes KC. Nerve supply of the human knee and its functional
importance. American Journal of Sports Medicine. 1982;10(6):329-335.

38.

Dye SF, Vaupel GL, Dye CC. Conscious neurosensory mapping of the internal structures
of the human knee without intraarticular anesthesia. American Journal of Sports
Medicine. 1998;26(6):773-777.

39.

Rutherford OM, Jones DA, Newham DJ. Clinical and experimental application of the
percutaneous twitch superimposition technique for the study of human muscle activation.
Journal of Neurology, Neurosurgery & Psychiatry. 1986;49(11):1288-1291.

40.

Doxey G, Eisenman P. The Influence of Patellofemoral Pain on Electromyographic
Activity during Submaximal Isometric Contractions. Journal of Orthopaedic and Sports
Physical Therapy. 1987;9(6):211-216.

41.

Eriksson E. Rehabilitation of muscle function after sport injury - major problem in sports
medicine. International Journal of Sports Medicine. 1981;2(1):1-6.

21

42.

Mellor R, Hodges PW. Motor unit syncronization is reduced in anterior knee pain.
Journal of Pain. 2005;6(8):550-558.

43.

Martin DN, Baehrecke EH. Caspases function in autophagic programmed cell death in
Drosophila. Development. 2004;131(2):275-284.

44.

Suter E, Herzog W, Bray RC. Quadriceps inhibition following arthroscopy in patients
with anterior knee pain. Clinical Biomechanics. 1998;13(4-5):314-319.

45.

Suter E, Herzog W, De Souza K, Bray R. Inhibition of the Quadriceps Muscles in
Patients With Anterior Knee Pain. Journal of Applied Biomechanics. 1998;14(4):360.

46.

Suter E, McMorland G, Herzog W, Bray R. Decrease in quadriceps inhibition after
sacroiliac joint manipulation in patients with anterior knee pain. Journal of Manipulative
and Physiological Therapeutics. 1999;22(3):149-153.

47.

Cowan SM, Hodges PW, Bennell KL, Crossley KM. Altered vastii recruitment when
people with patellofemoral pain syndrome complete a postural task. Archives Physical
Medicine and Rehabilitation. 2002;83(7):989-995.

48.

Suter E, McMorland G, Herzog W, Bray R. Conservative lower back treatment reduces
inhibition in knee extensor muscles: A randomized controlled trial. Journal of
Manipulative and Physiological Therapeutics. 2000;23(2):76-80.

49.

Arvidsson I, Eriksson E, Knutsson E, Arnér S. Reduction of pain inhibition on voluntary
muscle activation by epidural analgesia. Orthopedics. 1986;9(10):1415-1419.

50.

Shakespeare DT, Stokes M, Sherman KP, Young A. Reflex inhibition of the quadriceps
after meniscectomy-lack of association with pain. Clinicla Physiology. 1985;5(2):137144.

22

51.

Rice DA, McNair PJ. Quadriceps arthrogenic muscle inhibition: neural mechanisms and
treatment perspectives. Seminars in Arthritis and Rheumatism. 2010;40(3):250-266.

52.

Shrader MW, Draganich LF, Pottenger LA, Piotrowski GA. Effects of knee pain relief in
osteoarthritis on gait and stair-stepping. Clinical Orthopaedics & Related Research.
2004;421:188-193.

53.

Gandevia SC. Some central and peripheral factors affecting human motoneuronal output
in neuromuscular fatigue. Sports Medicine. 1992;13(2):93-98.

54.

Jones DA, Bigland-Ritchie B, Edwards RH. Excitation frequency and muscle fatigue:
mechanical responses during voluntary and stimulated contractions. Experimental
Neurology. 1979;64(2):401-413.

55.

Stackhouse SK, Dean JC, Lee SC, Binder-MacLeod SA. Measurement of central
activation failure of the quadriceps femoris in healthy adults. Muscle & Nerve.
2000;23(11):1706-1712.

56.

Hunt MA, Birmingham TB, Giffin JR, Jenkyn TR. Associations among knee adduction
moment, frontal plane ground reaction force, and lever arm during walking in patients
with knee osteoarthritis. Journal of Biomechanics. 2006;39(12):2213-2220.

57.

Stokes M, Young A. The contribution of refelx inhibition to arthrogenous muscle
weakness. Clinical Science. 1984;67(1):7-14.

58.

Young A. Current issues in arthrogenous inhibition. Annals of Rheumatic Diseases.
1993;52(11):829-834.

59.

Messier SP, Loeser RF, Hoover JL, Semble EL, Wise CM. Osteoarthritis of the knee:
effects on gait, strength, and flexibility. Archives of Physical Medicine & Rehabilitation.
1992;73(1):29-36.

23

60.

Roemhildt ML, Coughlin KM, Peura GD, et al. Effects of increased chronic loading on
articular cartilage material properties in the Lapine tibio-femoral joint. Journal of
Biomechanics. 2010;43(12):2301-2308.

24

Figure 1. CAR electrodes placement

25

Figure 2. Biodex seated position
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Figure 3. Infusion placement
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Figure 4. Supine position
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Figure 5. Seated position
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Figure 6. Standing position
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Figure 7. TENS electrodes placement
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Figure 8. Sham treatment (indicator light is on)
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Figure 9. Peceived knee pain normalized to the preinfusion (baseline) measurement. Knee pain
peaked at 4 cm in both groups (P < 0.0001). While perceived pain gradually decreased to 1.25
cm follwing TENS treatment, knee pain remained consistent across time at 3.42 cm following
sham treatment. Perceived pain was different from 6 min to 48 min, the only exception was at 38
min in the TENS group. Perceived pain was different from 6 min to 48 min in the sham group
relative to the preinfusion measurement.
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Figure 10. Knee extension MVIC normalized to the preinfusion (baseline) measurement. The
MVIC under knee pain in the TENS group was only different during infusion (P < 0.05).
However, the MVIC under knee pain in the sham group was different during infusion, treatment,
and posttreatment (P < 0.05).
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Figure 11. Knee extension CAR normalized to the preinfusion (baseline) measurement. The
CAR under knee pain in the TENS group was only different during infusion (P < 0.05).
However, the CAR under knee pain in the sham group was different during infusion, treatment,
and posttreatment (P < 0.05).
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Figure 12a. Difference between preinfusion and infusion VGRF in the TENS group
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Figure 12b. Infusion VGRF–preinfusion VGRF in the TENS group
Figure 12. Functional analysis of VGRF under knee pain between preinfusion and infusion factors in the
TENS group. Shaded areas represent 95% confidence intervals. Significant differences are defined by any
area where the edges of the confidence intervals are separated from the dotted line. Less deviation
represents decreased VGRF, while greater deviation represents increased VGRF between factors. VGRF
was decreased at heel-strike (0% to 4%), initial loading response (16% to 32%), and terminal stance phase
(69% to 91%). VGRF was increased at midstance phase (44% to 58%), compared to the preinfusion
measurement (α = 0.05).
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Figure 13a. Difference between preinfusion and treatment VGRF in the TENS group
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Figure 13b. Treatment VGRF–preinfusion VGRF in the TENS group
Figure 13. Functional analysis of VGRF under knee pain between preinfusion and treatment
factors in the TENS group. VGRF was only decreased at loading response (20% to 32%) and
terminal stance phase (76% to 86%) following TENS treatment, compared to the preinfusion
measurement.

37

preinfusion
posttreatment

1.2
1

VGRF (BW)

0.8
0.6
0.4
0.2
0

0

10

20

30

40
50
60
Time (% of Stance)

70

80

90

100

Figure 14a. Difference between preinfusion and posttreatment VGRF in the TENS group
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Figure 14b. Posttreatment VGRF–preinfusion VGRF in the TENS group
Figure 14. Functional analysis of VGRF under knee pain between preinfusion and posttreatment
factors in the TENS group. VGRF was decreased at initial heel-strike (1% to 4%) and loading
response phase (16% to 26%), compared to the preinfusion measurement.
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Figure 15a. Difference between preinfusion and infusion VGRF in the sham group
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Figure 15b. Infusion VGRF–preinfusion VGRF in the sham group
Figure 15. Functional analysis of VGRF under knee pain between preinfusion and infusion
factors in the sham group. VGRF was decreased at initial loading response (0% to 31%) and
terminal stance phase (66% to 84%), compared to the preinfusion measurement.
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Figure 16a. Difference between preinfusion VGRF and treatment VGRF in the sham group
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Figure 16b. Treatment VGRF–preinfusion VGRF in the sham group
Figure 16. Functional analysis of VGRF in the sham group under knee pain between preinfusion
and treatment factors. VGRF was decreased at initial heel-strike (1% to 10%), loading response
(18% to 30%), and terminal stance phase (70% to 94%). VGRF was increased at midstance
phase (42% to 45%) following sham treatment, compared to the preinfusion measurement.
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Figure 17a. Difference between preinfusion VGRF and posttreatment VGRF in the sham group
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Figure 17b. Posttreatment VGRF – preinfusion VGRF in the sham group
Figure 17. Functional analysis of VGRF under knee pain between preinfusion and posttreatment
factors in the sham group. VGRF was decreased at loading response (22% to 28%) and terminal
stance phase (70% to 92%). VGRF was increased at midstance phase (41% to 61%), compared
to the preinfusion measurement.
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